SCHEMBL386982

SCHEMBL386982

FC(F)(F)c1cccc(CCCI)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.62
MIF P14174 2/20 0.53
HDAC1 Q13547 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
IDO1 P14902 2/20 0.51
HTR2C P28335 3/20 0.50
HTR2B P41595 3/20 0.50
HTR2A P28223 2/20 0.50
ACP3 P15309 1/20 0.49
CYP2D6 P10635 2/20 0.48
SIGMAR1 Q99720 2/20 0.48
TP53 P04637 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
TSHR P16473 1/20 0.48
CYP2C19 P33261 1/20 0.48
DAO P14920 2/20 0.48
GAA P10253 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3624339 0.89 TAAR1 (0.67) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL7548352 0.87 TAAR1 (0.65) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL1045499 0.85 TAAR1 (0.62) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL1044826 0.84 TAAR1 (0.61) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL11383498 0.83 TAAR1 (0.65) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL1047616 0.82 TAAR1 (0.59) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL4664652 0.81 TAAR1 (0.62) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL1046263 0.81 TAAR1 (0.62) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL1723183 0.81 TAAR1 (0.62) TAAR1MIFHDAC1HDAC8IDO1
SCHEMBL21913967 0.81 TAAR1 (0.62) TAAR1MIFHDAC1HDAC8IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8969623-B2 Method for the preparation of cinacalcet and intermediates and impurities thereof Amneal Pharmaceuticals, LLC (US) 2015-03-03 US claimed
EP-2406211-A2 A NEW METHOD FOR THE PREPARATION OF CINACALCET AND NEW INTERMEDIATES THEREOF Megafine Pharma (P) Ltd. (IN) 2012-01-18 EP claimed
WO-2010103531-A2 A NEW METHOD FOR THE PREPARATION OF CINACALCET AND NEW INTERMEDIATES THEREOF MEGAFINE PHARMA (P) LTD. (IN) 2010-09-16 WO claimed
EP-2406211-B1 A NEW METHOD FOR THE PREPARATION OF CINACALCET AND NEW INTERMEDIATES THEREOF MEGAFINE PHARMA P LTD (IN) 2018-06-27 EP disclosed
US-20150152040-A1 Method For The Preparation Of Cinacalcet And Intermediates And Impurities Thereof AMNEAL PHARMACEUTICALS LLC (US) 2015-06-04 US disclosed
US-8969623-B2 Method for the preparation of cinacalcet and intermediates and impurities thereof Amneal Pharmaceuticals, LLC (US) 2015-03-03 US disclosed
US-20140081048-A1 Method For The Preparation Of Cinacalcet And Intermediates And Impurities Thereof MEGAFINE PHARMA (P) LTD. (IN) 2014-03-20 US disclosed
US-8575395-B2 Method for the preparation of cinacalcet and intermediates and impurities thereof Amneal Pharmaceuticals, LLC (US) 2013-11-05 US disclosed
US-8101650-B2 Method for treating a immunology-related disease DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-24 US disclosed
EP-2406211-A2 A NEW METHOD FOR THE PREPARATION OF CINACALCET AND NEW INTERMEDIATES THEREOF Megafine Pharma (P) Ltd. (IN) 2012-01-18 EP disclosed
EP-2406211-A2 A NEW METHOD FOR THE PREPARATION OF CINACALCET AND NEW INTERMEDIATES THEREOF Megafine Pharma (P) Ltd. (IN) 2012-01-18 EP disclosed
US-20090326038-A1 Method for treating a immunology-related disease SANKYO COMPANY, LIMITED (JP) 2009-12-31 US disclosed
US-7638551-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2009-12-29 US disclosed
EP-1471054-B1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE DAIICHI SANKYO CO LTD (JP) 2009-07-01 EP disclosed
US-20070142335-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2007-06-21 US disclosed
US-20070105933-A1 Amino alcohol compounds SANKYO COMPANY, LIMITED (JP) 2007-05-10 US disclosed
US-7199150-B2 Amino alcohol compounds SANKYO COMPANY, LIMITED (JP) 2007-04-03 US disclosed
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these SANKYO COMPANY, LIMITED (JP) 2005-02-24 US disclosed
EP-1471054-A1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE Sankyo Company, Limited (JP) 2004-10-27 EP disclosed
US-4004016-A ANTIINFLAMMATORY E. R. SQUIBB & SONS, INC. (US) 1977-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these PHOSPHO1, CD4, FCGRT TAAR1 218/4885MIF 2823/4885HDAC1 2849/4885
US-20140081048-A1 Method For The Preparation Of Cinacalcet And Intermediates And Impurities Thereof CMA1, SI, ALDH1A1 TAAR1 1331/4885MIF 2084/4885HDAC1 1038/4885
US-20090326038-A1 Method for treating a immunology-related disease C3AR1, HRH3, HRH2 TAAR1 309/4885MIF 1371/4885HDAC1 1486/4885
US-20070105933-A1 Amino alcohol compounds ADH1C, C9, SSB TAAR1 28/4885MIF 2304/4885HDAC1 2360/4885
US-20070142335-A1 Amino alcohol compounds or phosphonic acid derivatives thereof HRH3, C3AR1, HRH4 TAAR1 71/4885MIF 1321/4885HDAC1 1903/4885
US-20150152040-A1 Method For The Preparation Of Cinacalcet And Intermediates And Impurities Thereof CMA1, SI, ALDH1A1 TAAR1 1331/4885MIF 2084/4885HDAC1 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.